Primary

Inclusion Criteria:

- At least 20 years of age

- Histologically or cytologically confirmed gastric carcinoma, including gastric or
gastroesophageal-junction adenocarcinoma.

- Measurable disease (revised RECIST) based on computed tomography, or nonmeasurable
disease

- Previously untreated, unresectable advanced (M0) or unresectable metastatic (M1)
disease except for prior adjuvant (or neo-adjuvant) chemotherapy.

- ECOG performance status 0 or 1

- At least 4 weeks and recovery from effects of prior major surgery

- Adequate bone marrow, hepatic, and renal function

Primary Exclusion Criteria:

- Operable gastric or gastroesophageal-junction cancer

- Known brain metastasis

- Second cancer

- Previous adjuvant or neo-adjuvant chemotherapy with capecitabine and cisplatin in
combination. (Previous adjuvant or neo-adjuvant monotherapy with capecitabine or S-1
or therapy with S-1 and cisplatin in combination or 5-FU and cisplatin in combination
is allowed.)

- Uncontrolled diarrhea

- Nausea or vomiting for at least 3 consecutive days within the 14 days prior to
registration despite the administration of standard antiemetic therapy

- Symptomatic peripheral neuropathy ≥ Grade 2

- Malabsorption syndrome or other disease that significantly affects gastrointestinal
function

- Other uncontrolled systemic illness